Literature DB >> 773111

Distribution of immunoglobulin-containing cells in human bone marrow and lymphoid tissues.

I Turesson.   

Abstract

Cell suspensions of human bone marrow, spleen, lymph nodes and palatine tonsils have been investigated for the presence of intracellular immunoglobulins by a direct immunofluorescence technique, using monospecific antisera against human Ig heavy chains alpha, mu and gamma and light chains kappa and lambda. Serum Ig levels were determined and the number of positive cells was compared with the concentration and calculated synthetic rate of serum Ig in each individual. The 28 patients studied covered a wide range of diagnoses and included those with normal as well as pathologically decreased or increased serum Ig levels. There was a high correlation between the calculated synthetic rate of each Ig class and the percentage of cells positive for the same Ig class in the bone marrow but not in the spleen, lymph nodes or tonsils. The Ig-containing cells constituted a much larger proportion of the total lymphoid cell population in the bone marrow than in the peripheral lymphoid organs. The estimated total number of Ig-containing cells was also much larger in the bone marrow than in the other organs investigated. It is concluded that in man the bone marrow is the major site of serum Ig synthesis and that the average synthetic rate per cell is the same regardless which of the three major Ig classes is produced. The role played by different lymphoid organs in humoral immunity is discussed in the light of the present results and reported data regarding lymphocyte and plasma cell kinetics in mammals.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 773111     DOI: 10.1111/j.0954-6820.1976.tb06735.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  23 in total

1.  Immunoglobulin systems of human tonsils. I. Control subjects of various ages: quantification of Ig-producing cells, tonsillar morphometry and serum Ig concentrations.

Authors:  P Brandtzaeg; L Surjan; P Berdal
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

2.  Haematological features of angioimmunoblastic lymphadenopathy with dysproteinaemia.

Authors:  R L Brearley; J Chapman; M H Cullen; M A Horton; A G Stansfeld; A H Waters
Journal:  J Clin Pathol       Date:  1979-04       Impact factor: 3.411

3.  Local IgA subclass alterations in ulcerative colitis and Crohn's disease of the colon.

Authors:  K Kett; P Brandtzaeg
Journal:  Gut       Date:  1987-08       Impact factor: 23.059

4.  Extrathyroidal sites of autoantibody synthesis in Graves' disease.

Authors:  A P Weetman; A M McGregor; M H Wheeler; R Hall
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

5.  Immunohistochemical studies on various aspects of glandular immunoglobulin transport in man.

Authors:  P Brandtzaeg
Journal:  Histochem J       Date:  1977-09

6.  Frequencies of background cytoplasmic Ig-containing cells in various lymphoid organs of athymic asplenic (lasat), athymic, asplenic and normal BALB/c mice.

Authors:  A Van Oudenaren; J J Haaijman; R Benner
Journal:  Immunology       Date:  1981-03       Impact factor: 7.397

Review 7.  The bone marrow: the major source of serum immunoglobulins, but still a neglected site of antibody formation.

Authors:  R Benner; W Hijmans; J J Haaijman
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

Review 8.  The human intestinal B-cell response.

Authors:  J Spencer; L M Sollid
Journal:  Mucosal Immunol       Date:  2016-07-27       Impact factor: 7.313

9.  Frequencies of background cytoplasmic Ig-containing cells in various lymphoid organs of athymic and euthymic mice as a function of age and immune status.

Authors:  A Van Oudenaren; J J Haaijman; R Benner
Journal:  Immunology       Date:  1984-04       Impact factor: 7.397

10.  Murine intestinal antibody response to heterologous rotavirus infection.

Authors:  A A Merchant; W S Groene; E H Cheng; R D Shaw
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.